Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05165394 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD
A Phase 2 study, sponsored by Neurocrine Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
NCT05165394 is a Phase 2 study that has completed, run by Neurocrine Biosciences. The registered enrollment target is 93 participants.
The verdict
NCT05165394, a Phase 2 study, has completed, sponsored by Neurocrine Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
Study Summary
To evaluate the efficacy of NBI-1065846 compared with placebo on improving symptoms of anhedonia in participants with major depressive disorder (MDD).
Interventions
- DRUG Placebo
- DRUG NBI-1065846
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2021-11-30 |
| Est. Completion | 2023-09-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05165394
The ClinicalTrials.gov registry entry for NCT05165394 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05165394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05165394 about?
NCT05165394 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD". To evaluate the efficacy of NBI-1065846 compared with placebo on improving symptoms of anhedonia in participants with major depressive disorder (MDD).
What is the current status of trial NCT05165394?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2021-11-30. Estimated completion is 2023-09-13.
What interventions are being tested in trial NCT05165394?
The interventions under investigation include: Placebo (DRUG), NBI-1065846 (DRUG).
Who is sponsoring clinical trial NCT05165394?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.